trending Market Intelligence /marketintelligence/en/news-insights/trending/g1cOFZqzDHSlSrmpcaqqAA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Relief Therapeutics to sell subsidiary to Sonnet BioTherapeutics

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Relief Therapeutics to sell subsidiary to Sonnet BioTherapeutics

Geneva-based Relief Therapeutics Holding AG agreed to sell its Relief Therapeutics SA unit to SONNET BioTherapeutics Inc.

Sonnet BioTherapeutics is a Princeton, N.J.-based, privately held biotechnology company developing a pipeline of cancer-fighting immunotherapies using its proprietary platform.

Under the deal, Sonnet will issue 7,111,947 common shares to Relief and assume the development of SON-080, or atexakin alfa, a potential treatment of peripheral neuropathy — conditions involving damage to the peripheral nervous system.

Available pre-clinical data for SON-080, licensed by Relief Therapeutics SA from MERCK KGaA's Ares Trading SA subsidiary, showed that the investigational drug has the potential to treat neuropathies. Sonnet will develop atexakin in chemotherapy induced peripheral neuropathy and other indications, including diabetic neuropathy or nerve damage due to diabetes.

Completion of the transaction is expected to occur at the same time as Sonnet's public trading debut, subject to customary closing conditions.